Recombinant Therapeutic Protein Market Key Findings by 2031
A recombinant protein therapy is fashioned through recombinant DNA technology, which deal with the insertion of the DNA encoding protein into mammalian or bacterial cells. Majority of the biologics, such as monoclonal antibodies, are recombinant protein therapies which are widely used for several health related conditions. Increasing number of research and development activities are projected to drive the market during the forecast period.
MARKET DYNAMICS
The Recombinant Therapeutic Protein Market growth is prominently attributed to increasing prevalence of chronic conditions. Additionally, growing awareness of benefits offered by these therapeutic proteins are also anticipated to drive the market growth.
MARKET SCOPE
The "Recombinant Therapeutic Protein Market Analysis to 2031" is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of Recombinant Therapeutic Protein Market with detailed market segmentation by drug class and application. The recombinant therapeutic protein market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Recombinant Therapeutic Protein Market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Recombinant Therapeutic Protein Market is segmented on the basis of drug class and application. Based on drug class, the market is segmented as plasma protein, growth factors, fusion proteins, monoclonal antibodies, hormones, enzyme, coagulation factors, and others. On the basis of applications, the market is categorized as oncology, hematology, immunology, endocrinology, cardiovascular disease, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Recombinant Therapeutic Protein Market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Recombinant Therapeutic Protein Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Recombinant Therapeutic Protein Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Recombinant Therapeutic Protein Market in these regions.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Recombinant Therapeutic Protein Market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Recombinant Therapeutic Protein Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Recombinant Therapeutic Protein Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Recombinant Therapeutic Protein Market in these regions.
MARKET PLAYERS
The report covers key developments in the Recombinant Therapeutic Protein Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Recombinant Therapeutic Protein Market are anticipated to have lucrative growth opportunities in the future with the rising demand for radiotherapy devices in the global market. Below mentioned is the list of few companies engaged in the Recombinant Therapeutic Protein Market.
The report also includes the profiles of key players in Recombinant Therapeutic Protein Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Bristol-Myers Squibb
- Celldex Therapeutics, Inc.
- Eli Lilly and Company
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Novartis International AG
- Schering AG
- Johnson & Johnson
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Recombinant Therapeutic Protein Market - By Drug Class
1.3.2 Recombinant Therapeutic Protein Market - By Application
1.3.3 Recombinant Therapeutic Protein Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RECOMBINANT THERAPEUTIC PROTEIN MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RECOMBINANT THERAPEUTIC PROTEIN MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RECOMBINANT THERAPEUTIC PROTEIN MARKET - GLOBAL MARKET ANALYSIS
6.1. RECOMBINANT THERAPEUTIC PROTEIN - GLOBAL MARKET OVERVIEW
6.2. RECOMBINANT THERAPEUTIC PROTEIN - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. RECOMBINANT THERAPEUTIC PROTEIN MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. PLASMA PROTEIN
7.3.1. Overview
7.3.2. Plasma Protein Market Forecast and Analysis
7.4. GROWTH FACTORS
7.4.1. Overview
7.4.2. Growth Factors Market Forecast and Analysis
7.5. FUSION PROTEINS
7.5.1. Overview
7.5.2. Fusion Proteins Market Forecast and Analysis
7.6. MONOCLONAL ANTIBODIES
7.6.1. Overview
7.6.2. Monoclonal Antibodies Market Forecast and Analysis
7.7. HORMONES
7.7.1. Overview
7.7.2. Hormones Market Forecast and Analysis
7.8. ENZYME
7.8.1. Overview
7.8.2. Enzyme Market Forecast and Analysis
7.9. COAGULATION FACTORS
7.9.1. Overview
7.9.2. Coagulation Factors Market Forecast and Analysis
7.10. OTHERS
7.10.1. Overview
7.10.2. Others Market Forecast and Analysis
8. RECOMBINANT THERAPEUTIC PROTEIN MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ONCOLOGY
8.3.1. Overview
8.3.2. Oncology Market Forecast and Analysis
8.4. HEMATOLOGY
8.4.1. Overview
8.4.2. Hematology Market Forecast and Analysis
8.5. IMMUNOLOGY
8.5.1. Overview
8.5.2. Immunology Market Forecast and Analysis
8.6. ENDOCRINOLOGY
8.6.1. Overview
8.6.2. Endocrinology Market Forecast and Analysis
8.7. CARDIOVASCULAR DISEASE
8.7.1. Overview
8.7.2. Cardiovascular Disease Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. RECOMBINANT THERAPEUTIC PROTEIN MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Recombinant Therapeutic Protein Market Overview
9.1.2 North America Recombinant Therapeutic Protein Market Forecasts and Analysis
9.1.3 North America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.1.4 North America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.1.5 North America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.1.5.1 United States Recombinant Therapeutic Protein Market
9.1.5.1.1 United States Recombinant Therapeutic Protein Market by Drug Class
9.1.5.1.2 United States Recombinant Therapeutic Protein Market by Application
9.1.5.2 Canada Recombinant Therapeutic Protein Market
9.1.5.2.1 Canada Recombinant Therapeutic Protein Market by Drug Class
9.1.5.2.2 Canada Recombinant Therapeutic Protein Market by Application
9.1.5.3 Mexico Recombinant Therapeutic Protein Market
9.1.5.3.1 Mexico Recombinant Therapeutic Protein Market by Drug Class
9.1.5.3.2 Mexico Recombinant Therapeutic Protein Market by Application
9.2. EUROPE
9.2.1 Europe Recombinant Therapeutic Protein Market Overview
9.2.2 Europe Recombinant Therapeutic Protein Market Forecasts and Analysis
9.2.3 Europe Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.2.5 Europe Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Recombinant Therapeutic Protein Market
9.2.5.1.1 Germany Recombinant Therapeutic Protein Market by Drug Class
9.2.5.1.2 Germany Recombinant Therapeutic Protein Market by Application
9.2.5.2 France Recombinant Therapeutic Protein Market
9.2.5.2.1 France Recombinant Therapeutic Protein Market by Drug Class
9.2.5.2.2 France Recombinant Therapeutic Protein Market by Application
9.2.5.3 Italy Recombinant Therapeutic Protein Market
9.2.5.3.1 Italy Recombinant Therapeutic Protein Market by Drug Class
9.2.5.3.2 Italy Recombinant Therapeutic Protein Market by Application
9.2.5.4 Spain Recombinant Therapeutic Protein Market
9.2.5.4.1 Spain Recombinant Therapeutic Protein Market by Drug Class
9.2.5.4.2 Spain Recombinant Therapeutic Protein Market by Application
9.2.5.5 United Kingdom Recombinant Therapeutic Protein Market
9.2.5.5.1 United Kingdom Recombinant Therapeutic Protein Market by Drug Class
9.2.5.5.2 United Kingdom Recombinant Therapeutic Protein Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Recombinant Therapeutic Protein Market Overview
9.3.2 Asia-Pacific Recombinant Therapeutic Protein Market Forecasts and Analysis
9.3.3 Asia-Pacific Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Recombinant Therapeutic Protein Market
9.3.5.1.1 Australia Recombinant Therapeutic Protein Market by Drug Class
9.3.5.1.2 Australia Recombinant Therapeutic Protein Market by Application
9.3.5.2 China Recombinant Therapeutic Protein Market
9.3.5.2.1 China Recombinant Therapeutic Protein Market by Drug Class
9.3.5.2.2 China Recombinant Therapeutic Protein Market by Application
9.3.5.3 India Recombinant Therapeutic Protein Market
9.3.5.3.1 India Recombinant Therapeutic Protein Market by Drug Class
9.3.5.3.2 India Recombinant Therapeutic Protein Market by Application
9.3.5.4 Japan Recombinant Therapeutic Protein Market
9.3.5.4.1 Japan Recombinant Therapeutic Protein Market by Drug Class
9.3.5.4.2 Japan Recombinant Therapeutic Protein Market by Application
9.3.5.5 South Korea Recombinant Therapeutic Protein Market
9.3.5.5.1 South Korea Recombinant Therapeutic Protein Market by Drug Class
9.3.5.5.2 South Korea Recombinant Therapeutic Protein Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Recombinant Therapeutic Protein Market Overview
9.4.2 Middle East and Africa Recombinant Therapeutic Protein Market Forecasts and Analysis
9.4.3 Middle East and Africa Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Recombinant Therapeutic Protein Market
9.4.5.1.1 South Africa Recombinant Therapeutic Protein Market by Drug Class
9.4.5.1.2 South Africa Recombinant Therapeutic Protein Market by Application
9.4.5.2 Saudi Arabia Recombinant Therapeutic Protein Market
9.4.5.2.1 Saudi Arabia Recombinant Therapeutic Protein Market by Drug Class
9.4.5.2.2 Saudi Arabia Recombinant Therapeutic Protein Market by Application
9.4.5.3 U.A.E Recombinant Therapeutic Protein Market
9.4.5.3.1 U.A.E Recombinant Therapeutic Protein Market by Drug Class
9.4.5.3.2 U.A.E Recombinant Therapeutic Protein Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Recombinant Therapeutic Protein Market Overview
9.5.2 South and Central America Recombinant Therapeutic Protein Market Forecasts and Analysis
9.5.3 South and Central America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.5.5 South and Central America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Recombinant Therapeutic Protein Market
9.5.5.1.1 Brazil Recombinant Therapeutic Protein Market by Drug Class
9.5.5.1.2 Brazil Recombinant Therapeutic Protein Market by Application
9.5.5.2 Argentina Recombinant Therapeutic Protein Market
9.5.5.2.1 Argentina Recombinant Therapeutic Protein Market by Drug Class
9.5.5.2.2 Argentina Recombinant Therapeutic Protein Market by Application
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL RECOMBINANT THERAPEUTIC PROTEIN MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. RECOMBINANT THERAPEUTIC PROTEIN MARKET, KEY COMPANY PROFILES
12.1. BRISTOL-MYERS SQUIBB
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. CELLDEX THERAPEUTICS, INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ELI LILLY AND COMPANY
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. GLAXOSMITHKLINE PLC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. MERCK AND CO., INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. NOVARTIS INTERNATIONAL AG
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. SCHERING AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. JOHNSON AND JOHNSON
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Bristol-Myers Squibb
2. Celldex Therapeutics, Inc.
3. Eli Lilly and Company
4. GlaxoSmithKline plc
5. Merck & Co., Inc.
6. Novartis International AG
7. Schering AG
8. Johnson & Johnson
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For